De Jong K P, Stellema R, Karrenbeld A, Koudstaal J, Gouw A S, Sluiter W J, Peeters P M, Slooff M J, De Vries E G
Department of Surgery, Divisions of Hepato-Biliary Surgery and Liver Transplantation, University Hospital, Groningen, the Netherlands.
Hepatology. 1998 Oct;28(4):971-9. doi: 10.1002/hep.510280411.
To determine whether the expression of transforming growth factor alpha (TGF-alpha), its receptor (epidermal growth factor receptor [EGFr]), p53 nuclear protein, and proliferation influences prognosis of patients with liver metastases, a study was performed in 45 liver metastases and 33 corresponding primary colorectal carcinomas in patients referred for liver surgery. The expression of TGF-alpha, EGFr, p53 nuclear protein, and proliferation rate was correlated with clinicopathological characteristics and survival after partial liver resection. In liver metastases, TGF-alpha expression was low in 42%, intermediate in 35%, and high in 23%. TGF-alpha expression was higher in liver metastases derived from lymph node-positive primary carcinomas, in synchronous and in irresectable liver metastases compared with those derived from lymph node-negative primary carcinomas, metachronous, and resectable liver metastases. Nuclear p53 expression was found in 83% of primary tumors and 71% of liver metastases. p53 expression did not correlate with the various clinicopathological characteristics. Ki67 expression was not associated with clinicopathological characteristics in primary and metastatic tumors. In the 38 patients in whom a partial liver resection was performed, median survival was 25 months in patients with a higher TGF-alpha expression in the metastasis than in the primary tumor and 60 months in patients with comparable or lower TGF-alpha expression in the metastasis than in the primary tumor (P = .036). Median survival after liver resection was 21 months in patients with p53-negative liver metastases and 58 months in patients with p53-positive metastases (P = .043). By multivariate analysis, p53 and EGFr expression on liver metastases were the best predictors of disease-free survival after partial liver resection, with relative risks of 2.38 and 3.33, respectively. In patients with colorectal liver metastases, referred for liver surgery, a higher TGF-alpha expression is associated with unfavorable tumor characteristics, whereas p53 and absence of EGFr expression is associated with a better survival after partial liver resection.
为了确定转化生长因子α(TGF-α)及其受体(表皮生长因子受体[EGFr])、p53核蛋白的表达以及增殖情况是否会影响肝转移患者的预后,我们对45例肝转移患者以及33例相应的原发性结直肠癌患者进行了研究,这些患者均因肝脏手术前来就诊。TGF-α、EGFr、p53核蛋白的表达以及增殖率与临床病理特征及部分肝切除术后的生存率相关。在肝转移灶中,TGF-α表达低的占42%,中等的占35%,高的占23%。与源自淋巴结阴性原发性癌、异时性及可切除肝转移灶相比,源自淋巴结阳性原发性癌、同时性及不可切除肝转移灶中的TGF-α表达更高。在83%的原发性肿瘤和71%的肝转移灶中发现了核p53表达。p53表达与各种临床病理特征无关。Ki67表达与原发性和转移性肿瘤的临床病理特征无关。在接受部分肝切除的38例患者中,转移灶中TGF-α表达高于原发性肿瘤的患者中位生存期为25个月,转移灶中TGF-α表达与原发性肿瘤相当或低于原发性肿瘤的患者中位生存期为60个月(P = 0.036)。p53阴性肝转移患者肝切除术后的中位生存期为21个月,p53阳性转移患者为58个月(P = 0.043)。通过多因素分析,肝转移灶上的p53和EGFr表达是部分肝切除术后无病生存期的最佳预测指标,相对风险分别为2.38和3.33。在因肝脏手术前来就诊的结直肠癌肝转移患者中,较高的TGF-α表达与不良肿瘤特征相关,而p53和EGFr表达缺失与部分肝切除术后更好的生存率相关。